This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Feher, M. D Articles by Byrne, C. D Search for Related Content Social Bookmarking                         What's this?

Cost-outcome benefits of fibrate therapy in type 2 diabetes

Beta Cell Diabetes Centre, Chelsea & Westminster Hospital, London SW10, UK, m.feher{at}chelwest.nhs.uk

Clare E Langley-Hawthorne

Health Economics Group, Ethical Strategies Ltd, Surrey, UK

Christopher D Byrne

South Academic Block, Southampton General Hospital, UK

To date there have been few studies focusing on economic assessments of fibrate therapy in the management of coronary heart disease (CHD), particularly in patients with type 2 diabetes. A cost-effectiveness model for an economic analysis was established by an assessment of `cost per CHD event avoided' for fibrate therapy. This model was derived from: i) data on CHD events in patients with and without diabetes from randomised controlled trials of lipid-lowering agents, ii) comparisons of fibrate and HMG CoA reductase inhibitor (statin) treatment compared to no treatment and iii) current UK-based drug and clinical event costs. Treatment benefits over a five-year period were calculated, and the sensitivity of the model to the individual variables tested. Fibrate therapy was substantially more cost-effective than statin therapy in patients with diabetes. Economic costings for fenofibrate, as the index fibrate commonly used in the UK, confirmed an annual cost of £2,642— £3,700 per CHD event avoided over a five-year assessment period. Cost-effectiveness ratios derived in the economic model demonstrated that fibrate therapy was equally effective as statin therapy, but at a 54% reduction in annual cost. Current and future CHD treatment guidelines should incorporate pharmacoeconomic data for fibrate as well as statin therapy.

Key Words: diabetes • fibrate • cost-effectiveness • guidelines.

References

• Wilson PW, Kannel WB, Anderson KM Lipids, glucose tolerance and vascular disease. The Framingham Study. Monogr Atheroscler 1985;13:1-11.
• Stamler J., Vaccaro O., Neaton JD et al. Diabetes and other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.[Abstract]
• Haffner SM, Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
• Karlsson BW, Herlitz J., Hjalmarsson Å. Prognosis of acute myocardial infarction in diabetic and nondiabetic patients. Diabet Med 1993;10: 449-54.[Web of Science][Medline] [Order article via Infotrieve]
• Management of type 2 diabetes: Management of blood pressure and lipids. National Institute for Clinical Excellence. October 2002.
• American Diabetes Association. Clinical practice recommendations 2001. Management of dyslipidemia in adults with diabetes. Diabetes Care 2001;24:S1-S133.[CrossRef][Medline] [Order article via Infotrieve]
• Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. NICE 2001.
• Rubins HB, Robins CJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
• Sacks F., Pfeffer M., Moye L. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1995; 335:1001-09.[Web of Science]
• Robins S. Low HDL-C and coronary heart disease: the proper target for fibrate therapy. In HDL cholesterol: the missing link in cardiovascular risk reduction. Clinician 2000;18:14-17.
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
• British Heart Foundation Statistics Database 2000. British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford, 2000.
• Monthly Index of Medical Specialities. Haymarket Medical Ltd. London.
• Haffner SM, Asraf T. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents. Manag Care Interface 2000;13:52-8.[Medline] [Order article via Infotrieve]
• Perreault S., Hamilton VH, Lavoie F. et al. A head-to-head comparison of the cost-effectiveness of HMG CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drug Ther 1997; 10:787-94.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kirchgassler KU, Schiffner-Rohe J., Stahlheber U. Cost-effectiveness of micronized hyperlipidemia. Pharmacoeconomics 1997;12(2 Pt 2):237-46.[Web of Science][Medline] [Order article via Infotrieve]
• Guay DRP. Micronized fenofibrate: a new fibric acid hypolipidemia agent. Ann Pharmacother 1999;33:1083-103.[Abstract]
• The Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention study, a randomised study. Lancet 2001;357:905-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Durrington PN, Illingworth DR Lipid lowering drug therapy: more knowledge leads to more problems for composers of guidelines. Curr Opin Lipid 2000;11:345-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rubins HB, Robins SJ, Collins D. et al. Diabetes, plasma insulin and cardiovascular disease. Arch Intern Med 2002;162:2597-604.[Abstract/Free Full Text]
• Steiner G. Lipid intervention trials in diabetes. Diabetes Care 2000;23 (suppl 2):B49-B53.[Web of Science][Medline] [Order article via Infotrieve]
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
• Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Atherosclerosis 1998;140:199-270.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: a summary. BMJ 2000;320:705-08.[Free Full Text]
• Currie CJ, Kraus D., Morgan CL et al. NHS acute sector expenditure for diabetes: the present, future and excess in-patient cost of care. Diabet Med 1997;14:686-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Too many too late: A report by Diabetes UK. June 2001. www.diabetes.org.uk
• Colhoun HM, Dong W., Barakat MT, Mather HM, Poulter NR The scope of cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-1994. Diabet Med 1999;16:35-40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 2, 124-130 (2003)
DOI: 10.1177/14746514030030020801


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Feher, M. D Articles by Byrne, C. D Search for Related Content Social Bookmarking                         What's this?